Keros Therapeutics (KROS) Income towards Parent Company (2019 - 2025)

Keros Therapeutics has reported Income towards Parent Company for 7 years, with the latest figure at -$23.5 million in Q4 2025.

• For the quarter ending Q4 2025, Income towards Parent Company rose 49.03% year-over-year to -$23.5 million; the trailing twelve-month figure through Dec 2025 stood at $87.0 million (up 146.44% YoY), and the FY2025 full-year result was $87.0 million, up 146.44% from the prior year.
• Income towards Parent Company for Q4 2025 stood at -$23.5 million, down from -$7.3 million in the prior quarter.
• The five-year high for Income towards Parent Company was $148.5 million in Q1 2025, with the low at -$53.0 million in Q3 2024.
• Historically, Income towards Parent Company has averaged -$21.7 million across 5 years, with a median of -$28.5 million in 2022.
• Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 328.21% — and 2025, when it jumped 444.32%.
• Keros Therapeutics' Income towards Parent Company stood at -$6.9 million in 2021, then sank by 328.21% to -$29.7 million in 2022, then plunged by 56.32% to -$46.5 million in 2023, then increased by 0.92% to -$46.0 million in 2024, then soared by 49.03% to -$23.5 million in 2025.
• The last three Income towards Parent Company figures came in at -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025), per Business Quant data.